Table 2.
Erlotinib (n=38) | Cabozantinib (n=38) | Erlotinib plus Cabozantinib (n=35) | |
---|---|---|---|
Progression-free survival | |||
Deaths or disease progression | 36 (95%) | 34 (89%) | 30 (86%) |
Median progression-free survival, months (95% CI) | 1.8 (1.7–2.2) | 4.3 (3.6–7.4) | 4.7 (2.4–7.4) |
Overall survival | |||
Deaths | 30 (79%) | 29 (76%) | 19 (54%) |
Median overall survival, months (95% CI) | 5.1 (3.3–9.3) | 9.2 (5.1–15.0) | 13.3 (7.6-NR) |
Best overall response | |||
Complete response | 0 | 0 | 0 |
Partial response | 1 (3%) | 4 (11%) | 1 (3%) |
Stable disease | 6 (16%) | 19 (50%) | 16 (46%) |
Progressive disease | 25 (66%) | 9 (24%) | 8 (23%) |
Not evaluable/not assessed | 6 (16%) | 6 (16%) | 10 (29%) |
Data are n (%) unless otherwise indicated. NR = not reached